
Article 1 
The health claims set out in Annex I to this Regulation may be made on food on the  Great Britain  market in compliance with the conditions set out in that Annex.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 2 
 The health claims set out in Annex II to this Regulation may not be made on foods on the  Great Britain  market.
Article 3 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
...Done at Brussels, 29 October 2009.
For the Commission
Androulla VASSILIOU
Member of the Commission
ANNEX I
Application — Relevant provisions of Regulation (EC) No 1924/2006 Applicant — Address Nutrient, substance, food or food category Claim Conditions of use of the claim Conditions and/or restrictions of use of the food and/or additional statement or warning EFSA opinion reference
Article 14(1)(a) health claim referring to a reduction of a disease risk Leaf Int and Leaf Holland, Hoevestein 26, 4903 SC Oosterhout NB, The Netherlands, and Leaf Suomi Oy, PO Box 25, FI-21381 Aura, Finland Chewing gum sweetened with 100 % xylitol Chewing gum sweetened with 100 % xylitol has been shown to reduce dental plaque. High content/level of dental plaque is a risk factor in the development of caries in children Information to the consumer that the beneficial effect is obtained with a consumption of 2-3 g of chewing gum sweetened with 100 % xylitol at least 3 times per day after the meals  Q-2008-321
Article 14(1)(b) health claim referring to children’s development and health Danone SA, C/Buenos Aires, 21, 08029 Barcelona, Spain Phosphorus Phosphorus is needed for the normal growth and development of bone in children The claim can be used only for food which is at least a source of phosphorus as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006  Q-2008-217
ANNEX II
Application — Relevant provisions of Regulation (EC) No 1924/2006 Nutrient, substance, food or food category Claim EFSA opinion reference
Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral helps to bring back the normal functioning of the alimentary tract during its microflora disturbances (for example in case of loose stools, after taking antibiotics, in case of intestinal disorders caused by enteric pathogens) EFSA-Q-2008-269
Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral is recommended in order to improve the general immunity by maintaining the microbiological balance EFSA-Q-2008-477
Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral helps to protect the alimentary system against enteric pathogens because of strong antagonistic properties and helps to build the natural intestinal barrier EFSA-Q-2008-478
Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral helps to maintain natural intestinal microflora during travel, changing the climatic zone or a diet, especially in poor hygiene conditions EFSA-Q-2008-479
Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral contains living probiotic bacteria with strong ability to intestinal tract colonisation, isolated from healthy, naturally fed infant EFSA-Q-2008-480
Article 14(1)(b) health claim referring to children’s development and health Mumomega® Mumomega® provides the nourishments that support healthy central nervous system development EFSA-Q-2008-328
Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain coordination EFSA-Q-2008-121
Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain concentration EFSA-Q-2008-317
Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain and support brain development and function EFSA-Q-2008-318
Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain learning ability EFSA-Q-2008-319
Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain and support eye development and function EFSA-Q-2008-320
Article 14(1)(b) health claim referring to children’s development and health Eye q baby® Eye q baby® provides the nourishments that support healthy central nervous system development EFSA-Q-2008-119
Article 14(1)(b) health claim referring to children’s development and health Eye q® Eye q® provides the nourishments that help children to maintain healthy brain functions EFSA-Q-2008-329
Article 14(1)(b) health claim referring to children’s development and health Eye q® Eye q® provides the nourishments that help children to maintain concentration levels EFSA-Q-2008-330